Among patients with rheumatoid arthritis, observed rates of major adverse events from biologic/targeted synthetic DMARDs fell by about 25% in the years after market entry. This could be due to the ...

Therapy for inflammatory joint diseases, such as rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis, includes various conventional disease-modifying antirheumatic drugs (DMARDs).

The multicenter, Dutch, open-label, randomized controlled trial of 1142 patients with rheumatoid arthritis (RA; 61%), psoriatic arthritis (29%), or spondyloarthritis (10%) found that continuing ...

Neuroimmune modulation represents a promising treatment strategy that uses vagus nerve stimulation to reduce inflammation in ...

ACPAs can help doctors diagnose early rheumatoid arthritis (RA ... more to treatment with disease-modifying antirheumatic drugs (DMARDs) in the first year of therapy. The study also suggests ...

Rheumatoid arthritis (RA) patients in Denmark with a history of solid tumor cancers, now in remission, faced no greater ...

The Rheumatoid Arthritis Drugs/Therapeutics market revenue was $$ Million USD in 2022, grew to $$ Million USD in 2024, and will reach $$ Million USD in 2032, with a CAGR of $% during 2024-2032.

The global rheumatoid arthritis drugs market was valued at $57,929 million in 2019, and is projected to reach $62,935 million by 2027, registering a CAGR of 2.8% from 2020 to 2027. Alarming rise in ...